Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation
Open Access
- 15 September 2001
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 98 (6) , 1687-1694
- https://doi.org/10.1182/blood.v98.6.1687
Abstract
Delayed donor red cell engraftment and pure red cell aplasia (PRCA) are well-recognized complications of major ABO-incompatible hematopoietic stem cell transplantation (SCT) performed by means of myeloablative conditioning. To evaluate these events following reduced-intensity nonmyeloablative SCT (NST), consecutive series of patients with major ABO incompatibility undergoing either NST (fludarabine/cyclophosphamide conditioning) or myeloablative SCT (cyclophosphamide/high-dose total body irradiation) were compared. Donor red blood cell (RBC) chimerism (initial detection of donor RBCs in peripheral blood) was markedly delayed following NST versus myeloablative SCT (median, 114 versus 40 days;P < .0001) and strongly correlated with decreasing host antidonor isohemagglutinin levels. Antidonor isohemagglutinins declined to clinically insignificant levels more slowly following NST than myeloablative SCT (median, 83 versus 44 days;P = .03). Donor RBC chimerism was delayed more than 100 days in 9 of 14 (64%) and PRCA occurred in 4 of 14 (29%) patients following NST, while neither event occurred in 12 patients following myeloablative SCT. Conversion to full donor myeloid chimerism following NST occurred significantly sooner in cases with, compared with cases without, PRCA (30 versus 98 days; P = .008). Cyclosporine withdrawal appeared to induce graft-mediated immune effects against recipient isohemagglutinin-producing cells, resulting in decreased antidonor isohemagglutinin levels and resolution of PRCA following NST. These data indicate that significantly delayed donor erythropoiesis is (1) common following major ABO-incompatible NST and (2) associated with prolonged persistence of host antidonor isohemagglutinins. The clinical manifestations of these events are affected by the degree and duration of residual host hematopoiesis.Keywords
This publication has 44 references indexed in Scilit:
- Non-myeloablative stem cell transplants. AnnotationBritish Journal of Haematology, 2000
- CD34+ cell dose predicts relapse and survival after T‐cell‐depleted HLA‐identical haematopoietic stem cell transplantation (HSCT) for haematological malignanciesBritish Journal of Haematology, 2000
- Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantationBone Marrow Transplantation, 2000
- Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemiaTransplantation and Cellular Therapy, 1998
- Apheresis Therapy for Prolonged Red Cell Aplasia after Major ABO-Mismatched Bone Marrow Transplantation.Internal Medicine, 1997
- Pure red cell aplasia following ABO‐incompatible bone marrow transplantation: response to erythropoietinTransfusion, 1993
- Antibodies to histo‐blood group substances A and B: agglutination titers, Ig class, and IgG subclasses in healthy persons of different age categoriesTransfusion, 1991
- IMMUNOHEMATOLOGIC CONSEQUENCES OF MAJOR ABOMISMATCHED BONE MARROW TRANSPLANTATIONTransplantation, 1988
- Immunohematologic Problems Associated With Bone Marrow TransplantationTransfusion Medicine Reviews, 1987
- A and B blood group antigen expression on mixed colony cells and erythroid precursors: relevance for human allogeneic bone marrow transplantationBritish Journal of Haematology, 1984